Document is current
Any future updates will be listed below
-
Authors
Escobar-Doncel, Beatriz
Zhang, Xiaoyi
Ljøstad, Åsne
de la Puebla, Mario Fernández
Rao, Shreyas Balachandra
Fjeldstad, Synnøve Algrøy
Dahle, Maja Tvedt
Amiry-Moghaddam, Mahmood
Bjørås, Magnar
Fang, Evandro Fei
Tang, Wannan
-
Funding
Funding for this research was provided by:
Norges Teknisk-Naturvitenskapelige Universitet (Childhood dementia project)
Norges Forskningsråd (334361)
Norges Forskningsråd (262552)
Cure Alzheimer’s Fund (282952)
Helse Sør-Øst RHF (2020001)
Helse Sør-Øst RHF, Norway (2023093)
Molecule AG/VITADAO (282942)
NordForsk Foundation (119986)
National Natural Science Foundation of China (81971327)
Akershus Universitetssykehus (269901)
Akershus Universitetssykehus, Norway (262960)
Civitan Norges Forskningsfond for Alzheimers sykdom (281931)
Czech Republic-Norway KAPPA programme (TO01000215)
Rosa sløyfe/Norwegian Cancer Society & Norwegian Breast Cancer Society (207819)
HORIZON-TMA-MSCA-DN (101073251)
Wellcome Leap’s Dynamic Resilience Program (104617)
Helse Midt-Norge (28293)
Felles forskningsutvalg (34226)
NTNU Discovery (998012207)
- License Information
-
More Information
Article History
Received: 19 December 2025
Accepted: 18 May 2026
First Online: 26 May 2026
Competing interests
: W.T. is the owner of ProverBio Gene Consult AS (Organization number 936379117). E.F.F. is a co-owner of Fang-S Consultation AS (Organization number 931410717) and NO-Age AS (Organization number 933 219 127); he has an MTA with LMITO Therapeutics Inc (South Korea), a CRADA arrangement with ChromaDex (USA), a commercialization agreement with Molecule AG/VITADAO; he is a consultant to MindRank AI (China), NYO3 (Norway), and AgeLab (Vitality Nordic AS, Norway). Author E.F.F is an Editorial Board Member of journal npj Aging. E.F.F was not involved in the journal’s review of, or decisions related to, this manuscript. The other authors declare no competing financial or non-financial interests.
